AVTXAvalo Therapeutics, Inc.
Avalo Therapeutics, Inc. (AVTX) sells treatments targeting the IL-1β pathway for inflammatory diseases, with a focus on autoimmune and rheumatologic conditions. The next catalyst is Oct 15, 2026 — Fall 2026 Pipeline and Regulatory Update Window, which will test the company’s ability to advance its pipeline and secure regulatory clarity.
- Avalo is a small-cap biotech with a narrow therapeutic focus and limited near-term revenue.
- The company has a cash balance that’s critically tight, with a net loss of $107.38M in Q3 2025 and a free cash flow deficit of $113.68M in the trailing twelve months.
- The stock has shown volatility, with a 10% rally after Q1 2026 earnings matched estimates, but the market focused on its cash balance and losses.
The Read
3% after Q1 2026 earnings matched estimates but highlighted a critically tight cash balance and net losses, then rallied 10%.
The schedule
- Thu15Oct
The update tests whether the company can demonstrate progress on its pipeline and regulatory hurdles, which historically have been a key driver of investor sentiment and valuation.
- Thu5Nov
Earnings will test the company's ability to meet or exceed expectations on revenue, guidance, and cash flow, with a focus on how the recent equity raise and pipeline progress are reflected in the results.
- Mon15Mar
The full-year results and cash runway guidance will test the company's ability to deliver on its long-term strategy, with a focus on how the recent equity raise and pipeline progress are reflected in the results.
- Mon10May
The earnings release will test the company's ability to deliver on its operational performance and guidance, with a focus on how the recent equity raise and pipeline progress are reflected in the results.
- Wed21Jul
- Wed20Oct
Past
- Thu6Aug
Actual outcome: Bull · $20.05 at outcome
Avalo Therapeutics reported Q2 2026 earnings with an EPS of -$0.98, exactly matching consensus estimates. The stock rallied well past the bull target as investors reacted positively to the company's business updates and clinical progress targeting the IL-1β pathway, which provided reassuring clarity on their operational burn rate and development timelines.
The Q2 2026 earnings print will reveal the operational burn rate following anticipated mid-year capital actions, alongside updated clinical timelines.
- Wed15Jul
Actual outcome: Bull · $19.59 at outcome
Avalo Therapeutics shares rallied to surpass the $19.50 bull target as management actively engaged with investors at the Leerink Partners Therapeutics Forum and the BTIG Biotechnology Conference. The positive price action was driven by these strategic presentations, which helped bolster confidence in the company's IL-1β pathway pipeline and its ability to navigate its liquidity overhang.
AVTX enters Q3 2026 facing a critical liquidity overhang, necessitating an equity financing or strategic capital raise to extend its cash runway.
- Wed13May
Actual outcome: Bear · $15.40 at outcome
Stock fell 22.4% from event to outcome date, aligning with the bear trajectory.
Avalo's Q1 print arrives with shares trading near 52-week highs, creating a demanding setup as the market scrutinizes a critically tight cash balance of $24.98M against quarterly net losses of $19.6M.
